A 58-year-old man with newly diagnosed metastatic non-small-cell lung cancer (NSCLC) is planned for first-line chemotherapy. He has a history of severe constipation and bowel obstruction 2 years ago (managed medically). His baseline hemoglobin is 9.2 g/dL and platelets are 95,000/μL. The oncologist is choosing between paclitaxel and docetaxel as the microtubule inhibitor component. Which toxicity profile would MOST favor the choice of paclitaxel over docetaxel in this patient?

Explanation

## Taxane Comparison: Paclitaxel vs. Docetaxel ### Clinical Context The patient has a history of severe constipation and prior bowel obstruction. The oncologist must choose between paclitaxel and docetaxel. The question asks which toxicity profile would **most favor paclitaxel over docetaxel** in this specific patient. ### Toxicity Profile Comparison | Toxicity | Paclitaxel | Docetaxel | Clinical Relevance | |----------|-----------|-----------|--------------------| | **Fluid Retention/Edema** | Rare/Minimal | **Common (20–60%)** | Docetaxel's **signature toxicity**; requires prophylactic dexamethasone 3 days pre-treatment | | **Neutropenic Fever** | Moderate | Higher | Docetaxel has greater myelosuppression | | **GI Toxicity (Constipation/Diarrhea)** | Moderate | Moderate–Higher | Both agents require GI prophylaxis; difference is not universally emphasized as a major distinguishing factor | | **Hypersensitivity Reactions** | **Higher** (15–30% without premedication) | Lower | Paclitaxel requires routine premedication (dexamethasone, diphenhydramine, H2 blocker) | | **Peripheral Neuropathy** | High | High | Similar between both agents | | **Alopecia** | Common | Common | Similar incidence | ### Why Paclitaxel Is Favored Here **Key Point:** Fluid retention and edema is the **hallmark, signature toxicity of docetaxel**, occurring in 20–60% of patients and requiring mandatory prophylaxis with corticosteroids (dexamethasone 8 mg BID for 3 days starting the day before infusion). Paclitaxel rarely causes clinically significant fluid retention. In a patient with a history of bowel obstruction and baseline anemia/thrombocytopenia, avoiding docetaxel's cumulative fluid retention syndrome (which can cause pleural effusions, ascites, and peripheral edema) is the most textbook-supported, universally recognized reason to prefer paclitaxel. **High-Yield:** Docetaxel's fluid retention syndrome is cumulative and dose-dependent, and is the most consistently cited distinguishing toxicity between the two taxanes in standard pharmacology references (KD Tripathi, Harrison). This is the answer that is most robustly supported across all major texts. **Clinical Pearl:** While docetaxel may also cause more constipation than paclitaxel in some series, this difference is not as universally emphasized or as well-established as the fluid retention difference. The fluid retention/edema advantage of paclitaxel over docetaxel is the most reliable and textbook-consistent distinguishing feature. ### Why Other Options Are Incorrect **Option A – Lower risk of neutropenic fever:** Docetaxel does cause more myelosuppression, but this is not the most distinguishing or clinically relevant toxicity difference between the two agents in standard references. **Option B – Lower risk of GI toxicity and constipation:** While some data suggest docetaxel may cause more GI toxicity, this is not universally emphasized as a major distinguishing factor in standard pharmacology texts (KD Tripathi, Harrison). Both agents require GI prophylaxis. This is not the signature differentiating toxicity. **Option D – Lower risk of hypersensitivity reactions:** Paclitaxel actually has a **higher** risk of hypersensitivity reactions (15–30% without premedication) compared to docetaxel. This would favor docetaxel, not paclitaxel, making this option incorrect. [cite: KD Tripathi 8e Ch 62; Harrison 21e Ch 107; Brunton Goodman & Gilman 13e Ch 61]